TG Therapeutics, Inc. (TGTX) — Financial statements
Income statement, balance sheet, and cash flow for TG Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 616↑87.3% | 329↑40.8% | 234↑8290.0% | 3↓58.4% | 7 | |
| Cost of Revenue | 101↑161.7% | 38↑172.4% | 14↑5232.5% | 0.27↓66.5% | 0.79 | |
| Gross Profit | 516↑77.5% | 291↑32.3% | 220↑8611.5% | 3↓57.3% | 6 | |
| Operating Expenses | ||||||
| R&D Expenses | 160↑69.9% | 94↑23.8% | 76↓39.2% | 125↓43.7% | 223 | |
| General & Administrative Expenses | 232↑50.4% | 154↑25.7% | 123↑28.5% | 95↓25.5% | 128 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 232↑50.4% | 154↑25.7% | 123↑28.5% | 95↓25.5% | 128 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 392↑57.8% | 249↑25.0% | 199↓9.9% | 221↓37.0% | 351 | |
| Total Costs & Expenses | 493↑71.7% | 287↑34.8% | 213↓3.7% | 221↓37.1% | 351 | |
| Operating Results | ||||||
| Operating Income | 123↑194.1% | 42↑103.2% | 21↑109.5% | -218↑36.7% | -345 | |
| Depreciation & Amortization | 0.24↓12.9% | 0.28↓33.8% | 0.42↓17.9% | 0.52↑4.3% | 0.49 | |
| EBITDA | 134↑169.2% | 50↑91.2% | 26↑112.2% | -213↑37.7% | -342 | |
| EBIT | 134↑170.3% | 50↑93.3% | 26↑112.0% | -214↑37.6% | -342 | |
| Interest & Other Income | ||||||
| Net Interest Income | -27↓11.2% | -24↓90.5% | -13↓23.8% | -10↓80.8% | -6 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 27↑11.2% | 24↑90.5% | 13↑23.8% | 10↑80.8% | 6 | |
| Non-Operating Income | -11↓40.3% | -8↓52.5% | -5↓7.4% | -5↓103.5% | -2 | |
| Other Income / Expenses | -16↑2.5% | -16↓115.8% | -8↓37.8% | -5↓65.0% | -3 | |
| Income Before Tax | 107↑319.6% | 26↑95.9% | 13↑105.8% | -224↑35.7% | -348 | |
| Income Tax Expense | -340↓15468.1% | 2↑466.9% | 0.39 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 447↑1812.4% | 23↑84.5% | 13↑105.7% | -224↑35.7% | -348 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 447↑1812.4% | 23↑84.5% | 13↑105.7% | -224↑35.7% | -348 | |
| Bottom-Line Net Income | 447↑1812.4% | 23↑84.5% | 13↑105.7% | -224↑35.7% | -348 | |
| EPS (Basic) | 3.10↑1837.5% | 0.16↑79.2% | 0.09↑106.1% | -1.46↑44.5% | -2.63 | |
| EPS (Diluted) | 2.77↑1746.7% | 0.15↑75.8% | 0.09↑105.8% | -1.46↑44.5% | -2.63 | |
| Weighted Average Shares | 144↓0.7% | 145↑2.4% | 142↑4.8% | 135↑2.4% | 132 | |
| Weighted Average Diluted Shares | 161↑0.7% | 160↑8.0% | 149↑9.7% | 135↑2.4% | 132 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.